Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-α for infection control and treatment

References

• Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013;368(20):1888-97
   PubMed Web of Science ®Google Scholar
• Mei Z, Lu S, Wu X, et al. Avian influenza A(H7N9) virus infections, Shanghai, China. Emerg Infect Dis 2013;19(7):1179-81
   PubMedGoogle Scholar
• Salathe M, Freifeld CC, Mekaru SR, et al. Influenza A (H7N9) and the importance of digital epidemiology. N Engl J Med 2013;369(5):401-4
   PubMedGoogle Scholar
• Li Q, Zhou L, Zhou M, et al. Preliminary report: epidemiology of the Avian Influenza A (H7N9) outbreak in China. N Engl J Med 2013; Epub ahead of print
   Google Scholar
• Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013;381(9885):2273-9
   PubMed Web of Science ®Google Scholar
• To KK, Chan JF, Chen H, et al. The emergence of influenza A H7N9 in human beings 16 years after influenza A H5N1: a tale of two cities. Lancet Infect Dis 2013;13(9):809-21
   PubMed Web of Science ®Google Scholar
• Zhang Q, Shi J, Deng G, et al. H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science 2013;341(6144):410-14
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang D, Gao R, et al. Biological features of novel avian influenza A (H7N9) virus. Nature 2013;499(7459):500-3
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kiso M, Fukuyama S, et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature 2013;501(7468):551-5
   PubMed Web of Science ®Google Scholar
• Lam TT, Wang J, Shen Y, et al. The genesis and source of the H7N9 influenza viruses causing human infections in China. Nature 2013;502(7470):241-4
   PubMed Web of Science ®Google Scholar
• Hatta M, Gao P, Halfmann P, Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 2001;293(5536):1840-2
   PubMed Web of Science ®Google Scholar
• Belser JA, Gustin KM, Pearce MB, et al. Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice. Nature 2013;501(7468):556-9
   PubMed Web of Science ®Google Scholar
• Richard M, Schrauwen EJ, de Graaf M, et al. Limited airborne transmission of H7N9 influenza A virus between ferrets. Nature 2013;501(7468):560-3
   PubMed Web of Science ®Google Scholar
• Zhu H, Wang D, Kelvin DJ, et al. Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science 2013;341(6142):183-6
   PubMed Web of Science ®Google Scholar
• Ma W, Kahn RE, Richt JA. The pig as a mixing vessel for influenza viruses: human and veterinary implications. J Mol Genet Med 2008;3(1):158-66
   PubMedGoogle Scholar
• Schmidt AC. Antiviral therapy for influenza: a clinical and economic comparative review. Drugs 2004;64(18):2031-46
   PubMed Web of Science ®Google Scholar
• Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res 2008;78(1):91-102
   PubMedGoogle Scholar
• Grambas S, Bennett MS, Hay AJ. Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza A viruses. Virology 1992;191(2):541-9
   PubMed Web of Science ®Google Scholar
• Hay AJ, Hayden FG. Oseltamivir resistance during treatment of H7N9 infection. Lancet 2013;381(9885):2230-2
   PubMed Web of Science ®Google Scholar
• Yen HL, Herlocher LM, Hoffmann E, et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 2005;49(10):4075-84
   PubMed Web of Science ®Google Scholar
• Yen HL, McKimm-Breschkin JL, Choy KT, et al. Resistance. to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population. MBio 2013;4(4):e00396-13
   Google Scholar
• Rossignol JF, La Frazia S, Chiappa L, et al. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 2009;284(43):29798-808
   PubMed Web of Science ®Google Scholar
• Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013;100(2):446-54
   PubMed Web of Science ®Google Scholar
• Zhirnov OP, Klenk HD, Wright PF. Aprotinin and similar protease inhibitors as drugs against influenza. Antiviral Res 2011;92(1):27-36
   PubMed Web of Science ®Google Scholar
• Antonelli G. Biological basis for a proper clinical application of alpha interferons. New Microbiol 2008;31(3):305-18
   PubMed Web of Science ®Google Scholar
• Haasbach E, Droebner K, Vogel AB, Planz O. Low-dose interferon Type I treatment is effective against H5N1 and swine-origin H1N1 influenza A viruses in vitro and in vivo. J Interferon Cytokine Res 2011;31(6):515-25
   PubMed Web of Science ®Google Scholar
• Osterlund P, Pirhonen J, Ikonen N, et al. Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive to the antiviral actions of interferons. J Virol 2010;84(3):1414-22
   PubMed Web of Science ®Google Scholar
• Silverman RH. Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virol 2007;81(23):12720-9
   PubMed Web of Science ®Google Scholar
• Garcia MA, Gil J, Ventoso I, et al. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev 2006;70(4):1032-60
   PubMed Web of Science ®Google Scholar
• Haller O, Staeheli P, Kochs G. Interferon-induced Mx proteins in antiviral host defense. Biochimie 2007;89(6-7):812-18
   PubMed Web of Science ®Google Scholar
• Tan EL, Ooi EE, Lin CY, et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis 2004;10(4):581-6
   PubMedGoogle Scholar
• Strayer DR, Carter WA. Recombinant and natural human interferons: analysis of the incidence and clinical impact of neutralizing antibodies. J Interferon Cytokine Res 2012;32(3):95-102
   PubMed Web of Science ®Google Scholar
• Liu Q, Qiao C, Marjuki H, et al. Combination of PB2 271A and SR polymorphism at positions 590/591 is critical for viral replication and virulence of swine influenza virus in cultured cells and in vivo. J Virol 2012;86(2):1233-7
   PubMed Web of Science ®Google Scholar